The contraceptive pill remains a polarizing topic, praised by some as a cornerstone of women's emancipation and criticized by others for potential health risks. New research from experts at the University of Milan offers compelling evidence of its benefits: regular use appears to correlate with reduced ovarian cancer rates worldwide, though variations exist across countries.
Published on September 6, 2016, in the prestigious journal Annals of Oncology, the study links oral contraceptive use to a notable decline in ovarian cancer deaths. Across Europe, mortality rates fell by 10% from 2002 to 2012. The reductions were even steeper in specific nations: 22% in the United Kingdom, 24% in Denmark and Switzerland, 16% in the United States, 12% in New Zealand and Australia, and 8% in Canada. This trend underscores a global pattern of improvement.
In contrast, Japan—where oral contraceptive use is among the world's lowest—reports higher ovarian cancer rates than Europe or the U.S. This observation supports the hypothesis that the pill lowers risk. Researchers also point to reduced use of hormone replacement therapy (HRT) in postmenopausal women. A pivotal 2002 study highlighted HRT's links to increased cardiovascular disease, breast, and ovarian cancer risks, prompting widespread discontinuation. Whether the pill, declining HRT, or both drive these gains remains under investigation, but the results are undeniably positive for women's health.
